This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Pulmonary disease				
Pulmonary	Adenosine A _{2B} receptor	<i>In vitro</i> studies identified a new series of adenosine A _{2B} receptor antagonists that could be used to treat chronic pulmonary inflammation. <i>In vitro</i> , the newly synthesized class of xanthine-8-yl-benzenesulfonamide derivatives had activity against and selectivity for the A _{2B} receptor over human and mouse A ₁ and A _{2A} receptors and the human A ₃ receptor. Next steps include improving the compounds' solubility and pharmacokinetics. SciBX 2(23); doi:10.1038/scibx.2009.953 Published online June 11, 2009	Compounds unpatented; follow-up compounds in development could be available for licensing	Borrmann, T. <i>et al.</i> <i>J. Med. Chem.</i> ; published online May 27, 2009; doi:10.1021/jm900413e Contact: Christa E. Müller, PharmaCenter Bonn, Bonn, Germany e-mail: christa.mueller@uni-bonn.de